Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Autor: Assoumou, Lambert, Moyle, Graeme, Waters, Laura, Johnson, Margaret, Domingo, Pere, Fox, Julie, Stellbrink, Hans-Jürgen, Guaraldi, Giovanni, Masiá, Mar, Gompels, Mark, De Wit, Stephane, Florence, Eric, Esser, Stefan, Raffi, François, Behrens, Georg, Pozniak, Anton, Gatell, José M., Martínez, Esteban, Vandekerckhove, Linos, Caluwé, Els, Necsoi, Coca, Van Frankenhuijsen, Maartje, Allavena, Clotilde, Reliquet, Véronique, Boutoille, David, Cavellec, Morane, André-Garnier, Elisabeth, Rodallec, Audrey, Le Tourneau, Thierry, Connault, Jérôme, Molina, Jean-Michel, Ferret, Samuel, Previlon, Miresta, Yazdanpanah, Yazdan, Landman, Roland, Joly, Véronique, Pinto, Adriana, Katlama, Christine, Caby, Fabienne, Ktorza, Nadine, Schneider, Luminita, Stephan, Christoph, Wolf, Timo, Schüttfort, Gundolf, Rockstroh, Juergen, Wasmuth, Jan-Christian, Schwarze-Zander, Carolynne, Boesecke, Christoph, Stellbrink, Hans-Jurgen, Hoffmann, Christian, Sabranski, Michael, Jablonka, Robert, Wiehler, Heidi, Stoll, Matthias, Ahrenstorf, Gerrit, Nardini, Giulia, Beghetto, Barbara, Montforte, Antonella D'Arminio, Bini, Teresa, Cogliandro, Viola, Di Pietro, Massimo, Fusco, Francesco Maria, Galli, Massimo, Rusconi, Stefano, Giacomelli, Andrea, Meraviglia, Paola, Martinez, Esteban, González-Cordón, Ana, Gatell, José Maria, Torres, Berta, Mateo, Gracia, Gutierrez, Mar, Portilla, Joaquin, Merino, Esperanza, Reus, Sergio, Boix, Vicente, Masia, Mar, Gutiérrez, Félix, Padilla, Sergio, Clotet, Bonaventura, Negredo, Eugenia, Bonjoch, Anna, Casado, José L, Bañón-Escandell, Sara, Saban, Jose, Duque, Africa, Podzamczer, Daniel, Saumoy, Maria, Acerete, Laura, Gonzalez-Garcia, Juan, Bernardino, José Ignacio, Arribas, José Ramón, Hontañón, Victor, Pagani, Nicole, Bracchi, Margherita, Vera, Jaime, Clarke, Amanda, Adams, Tanya, Richardson, Celia, Winston, Alan, Mora-Peris, Borja, Mullaney, Scott, De Esteban, Nahum, Milinkovic, Ana, Pett, Sarah, Tiraboschi, Juan Manuel, Youle, Mike, Orkin, Chloe, Rackstraw, Simon, Hand, James, Jennings, Louise, Nicholls, Jane, Johnston, Sarah
Přispěvatelé: NEAT022 Study Grp
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
The journal of antimicrobial chemotherapy
ISSN: 0305-7453
Popis: Background Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this strategy may have an impact on cardiovascular biomarkers is unknown. Methods We assessed 48 week changes in biomarkers associated with inflammation, endothelial dysfunction, monocyte immune activation, oxidation, insulin resistance, hypercoagulability, heart failure, myocardial injury, and glomerular and tubular kidney injury. Results Of 415 PLWH randomized in the NEAT022 study, 313 (75.4%) remained on allocated therapy and had paired samples available. Soluble CD14 (–11%, P Conclusions Switching from boosted PIs to dolutegravir in PLWH with high cardiovascular risk led to soluble CD14 and adiponectin reductions at 48 weeks. While decreasing soluble CD14 may entail favourable health effects in PLWH, adiponectin reduction may reflect less insulin sensitivity associated with weight gain.
Databáze: OpenAIRE